Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors

Sampa Santra; Yue Sun; Birgit Korioth-Schmitz; Julie Fitzgerald; Cherie Charbonneau; Giannina Santos; Michael S. Seaman; Sarah J. Ratcliffe; David C. Montefiori; Gary J. Nabel; Hildegund C J Ertl; Norman L. Letvin

doi:10.1016/j.vaccine.2009.07.050

Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors

Sampa Santra, Yue Sun, Birgit Korioth-Schmitz, Julie Fitzgerald, Cherie Charbonneau, Giannina Santos, Michael S. Seaman, Sarah J. Ratcliffe, David C. Montefiori, Gary J. Nabel, Hildegund C J Ertl, Norman L. Letvin

Research output: Contribution to journal › Article

Abstract

Pre-existing immunity to human adenovirus serotype 5 (AdHu5) has been shown to suppress the immunogenicity of recombinant Ad5 (rAdHu5) vector-based vaccines for human immunodeficiency virus type 1 (HIV-1) in both preclinical studies and clinical trials. As a potential solution to this problem we developed adenovirus vaccine vectors of chimpanzee origin. In the present study we assessed the immunogenicity of various chimpanzee adenovirus vectors in a prime/boost regimen to HIV-1 envelope and SIV Gag-Pol in rhesus monkeys and their ability to protect against pathogenic viral challenge. Although rAdHu5-primed monkeys had higher magnitude T cell responses than rAdC7 or rAdC68 prior to challenge, the rAdC7-rAdC1/C5 and rAdHu5-rAdC1/C5 immunizations resulted in comparable magnitude recall cellular immune responses and comparable level of control of viremia post-challenge.

Original language	English (US)
Pages (from-to)	5837-5845
Number of pages	9
Journal	Vaccine
Volume	27
Issue number	42
DOIs	https://doi.org/10.1016/j.vaccine.2009.07.050
State	Published - Sep 25 2009
Externally published	Yes

Fingerprint

Keywords

Chimpanzee adenovirus
HIV-1 vaccine

ASJC Scopus subject areas

Immunology and Microbiology(all)
Infectious Diseases
Public Health, Environmental and Occupational Health
veterinary(all)
Molecular Medicine

Cite this

Santra, S., Sun, Y., Korioth-Schmitz, B., Fitzgerald, J., Charbonneau, C., Santos, G., Seaman, M. S., Ratcliffe, S. J., Montefiori, D. C., Nabel, G. J., Ertl, H. C. J., & Letvin, N. L. (2009). Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine, 27(42), 5837-5845. https://doi.org/10.1016/j.vaccine.2009.07.050

Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. / Santra, Sampa; Sun, Yue; Korioth-Schmitz, Birgit; Fitzgerald, Julie; Charbonneau, Cherie; Santos, Giannina; Seaman, Michael S.; Ratcliffe, Sarah J.; Montefiori, David C.; Nabel, Gary J.; Ertl, Hildegund C J; Letvin, Norman L.

In: Vaccine, Vol. 27, No. 42, 25.09.2009, p. 5837-5845.

Research output: Contribution to journal › Article

Santra, Sampa ; Sun, Yue ; Korioth-Schmitz, Birgit ; Fitzgerald, Julie ; Charbonneau, Cherie ; Santos, Giannina ; Seaman, Michael S. ; Ratcliffe, Sarah J. ; Montefiori, David C. ; Nabel, Gary J. ; Ertl, Hildegund C J ; Letvin, Norman L. / Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. In: Vaccine. 2009 ; Vol. 27, No. 42. pp. 5837-5845.

@article{9ae24b3bb3e94203b9d54a9d7a4810d4,

title = "Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors",

abstract = "Pre-existing immunity to human adenovirus serotype 5 (AdHu5) has been shown to suppress the immunogenicity of recombinant Ad5 (rAdHu5) vector-based vaccines for human immunodeficiency virus type 1 (HIV-1) in both preclinical studies and clinical trials. As a potential solution to this problem we developed adenovirus vaccine vectors of chimpanzee origin. In the present study we assessed the immunogenicity of various chimpanzee adenovirus vectors in a prime/boost regimen to HIV-1 envelope and SIV Gag-Pol in rhesus monkeys and their ability to protect against pathogenic viral challenge. Although rAdHu5-primed monkeys had higher magnitude T cell responses than rAdC7 or rAdC68 prior to challenge, the rAdC7-rAdC1/C5 and rAdHu5-rAdC1/C5 immunizations resulted in comparable magnitude recall cellular immune responses and comparable level of control of viremia post-challenge.",

keywords = "Chimpanzee adenovirus, HIV-1 vaccine",

author = "Sampa Santra and Yue Sun and Birgit Korioth-Schmitz and Julie Fitzgerald and Cherie Charbonneau and Giannina Santos and Seaman, {Michael S.} and Ratcliffe, {Sarah J.} and Montefiori, {David C.} and Nabel, {Gary J.} and Ertl, {Hildegund C J} and Letvin, {Norman L.}",

year = "2009",

month = sep,

day = "25",

doi = "10.1016/j.vaccine.2009.07.050",

language = "English (US)",

volume = "27",

pages = "5837--5845",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "42",

}

TY - JOUR

T1 - Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors

AU - Santra, Sampa

AU - Sun, Yue

AU - Korioth-Schmitz, Birgit

AU - Fitzgerald, Julie

AU - Charbonneau, Cherie

AU - Santos, Giannina

AU - Seaman, Michael S.

AU - Ratcliffe, Sarah J.

AU - Montefiori, David C.

AU - Nabel, Gary J.

AU - Ertl, Hildegund C J

AU - Letvin, Norman L.

PY - 2009/9/25

Y1 - 2009/9/25

N2 - Pre-existing immunity to human adenovirus serotype 5 (AdHu5) has been shown to suppress the immunogenicity of recombinant Ad5 (rAdHu5) vector-based vaccines for human immunodeficiency virus type 1 (HIV-1) in both preclinical studies and clinical trials. As a potential solution to this problem we developed adenovirus vaccine vectors of chimpanzee origin. In the present study we assessed the immunogenicity of various chimpanzee adenovirus vectors in a prime/boost regimen to HIV-1 envelope and SIV Gag-Pol in rhesus monkeys and their ability to protect against pathogenic viral challenge. Although rAdHu5-primed monkeys had higher magnitude T cell responses than rAdC7 or rAdC68 prior to challenge, the rAdC7-rAdC1/C5 and rAdHu5-rAdC1/C5 immunizations resulted in comparable magnitude recall cellular immune responses and comparable level of control of viremia post-challenge.

AB - Pre-existing immunity to human adenovirus serotype 5 (AdHu5) has been shown to suppress the immunogenicity of recombinant Ad5 (rAdHu5) vector-based vaccines for human immunodeficiency virus type 1 (HIV-1) in both preclinical studies and clinical trials. As a potential solution to this problem we developed adenovirus vaccine vectors of chimpanzee origin. In the present study we assessed the immunogenicity of various chimpanzee adenovirus vectors in a prime/boost regimen to HIV-1 envelope and SIV Gag-Pol in rhesus monkeys and their ability to protect against pathogenic viral challenge. Although rAdHu5-primed monkeys had higher magnitude T cell responses than rAdC7 or rAdC68 prior to challenge, the rAdC7-rAdC1/C5 and rAdHu5-rAdC1/C5 immunizations resulted in comparable magnitude recall cellular immune responses and comparable level of control of viremia post-challenge.

KW - Chimpanzee adenovirus

KW - HIV-1 vaccine

UR - http://www.scopus.com/inward/record.url?scp=69749121344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69749121344&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.07.050

DO - 10.1016/j.vaccine.2009.07.050

M3 - Article

C2 - 19660588

AN - SCOPUS:69749121344

VL - 27

SP - 5837

EP - 5845

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 42

ER -

Access to Document

10.1016/j.vaccine.2009.07.050